Hubungan antara Karakteristik dan Komorbid Pasien TB-MDR yang Mendapat Terapi BpaL/M dengan Kejadian Efek Samping Linezolid di Rumah Sakit Adam Malik Medan

Abstract

Tuberculosis (TB) is a disease with a high burden of treatment. Current MDR-TB therapy uses the BPaL/M (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin) combination. This combination has been shown to be effective with a short treatment duration. Linezolid is one of the components of the BPaL/M blend, but despite its effectiveness, Linezolid has side effects, which impact treatment management and success. This study was a retrospective analytic study of MDR-TB patients receiving BPaL/M combination. Data were collected from medical records and analyzed using the Fisher exact test, to analyze the association between patient characteristics and comorbidities with the incidence of Linezolid side effects, namely hematological disorders, peripheral neuropathy, and visual disturbances. There was no significant association between overall patient characteristics and the incidence of Linezolid adverse events. However, the results of bivariate analysis showed a significant association in age >50 years with the incidence of hematological disorders, as well as in patients who have comorbid type 2 diabetes mellitus with the incidence of peripheral neuropathy as a side effect of Linezolid. Stricter monitoring of TBMDR patients aged >50 years or those with comorbid type 2 diabetes mellitus to minimize the incidence of side effects during treatment is very important. This effort is expected to support the success of the national TB control and treatment program, so that the objectives of the TB eradication program can be achieved as expected.